Cerus Corporation 2012 Form 10-K Summary
Business context and reporting period
Cerus develops and commercializes the INTERCEPT Blood System, designed to inactivate pathogens in donated platelets, plasma and red blood cells. Platelet and plasma systems were commercialized in Europe, the Commonwealth of Independent States, the Middle East and selected other markets; the red blood cell system remained in clinical development. The filing covers the fiscal year ended December 31, 2012, with quarterly data for the three months ended December 31, 2012.
Financial performance and liquidity
| Metric | 2012 | 2011 | Change |
|---|---|---|---|
| Product revenue | $36.7 million | $30.6 million | 20% |
| Total revenue | $36.8 million | $33.0 million | 11% |
| Product gross profit | $16.1 million | $12.1 million | 33% |
| Product gross margin | 44% | 39% | Up 5 points |
| Operating loss | $(17.3) million | $(15.9) million | Loss increased |
| Net loss | $(15.9) million | $(17.0) million | Loss narrowed |
| Basic net loss per share | $(0.29) | $(0.35) | Improved |
| Cash used in operations | $(13.9) million | $(15.6) million | Improved |
Research and development expense was $7.6 million, compared with $7.2 million in 2011, while selling, general and administrative expense increased to $25.7 million from $23.1 million. Non-cash stock-based compensation was $2.5 million. A $2.1 million non-cash gain from revaluation of the warrant liability materially reduced the reported net loss.
At December 31, 2012, cash and cash equivalents were $26.7 million, working capital was $18.4 million and total stockholders’ equity was $19.1 million. Total debt was $7.7 million, consisting principally of a $4.6 million Comerica growth capital loan and $3.2 million drawn under a revolving credit facility. Debt is secured by substantially all assets other than intellectual property and certain subsidiary investment interests.
Financing activities provided $14.9 million in cash, including approximately $13.8 million of net proceeds from sales of common stock. The company had approximately $25.5 million remaining under its Cantor equity sales agreement at year-end. The company stated that available cash, product receipts and debt access were expected to fund requirements for at least the next twelve months, but continuing losses and development needs create ongoing financing risk.
Fourth-quarter results
| Metric | Q4 2012 | Q4 2011 |
|---|---|---|
| Product revenue | $10.5 million | $9.9 million |
| Product gross profit | $5.4 million | $3.7 million |
| Product gross margin | Approximately 51% | Approximately 37% |
| Operating loss | $(3.6) million | $(3.3) million |
| Net loss | $(1.7) million | $(7.7) million |
Fourth-quarter net loss benefited from $2.0 million of non-operating income, primarily the warrant-liability revaluation gain.
Material changes versus the prior comparable period
- Product revenue increased $6.1 million, primarily from higher disposable platelet and plasma kit volumes, new customers and a full year of sales from customers adopting during 2011. Illuminator sales declined.
- Product gross margin improved to 44% from 39%, principally because of lower per-unit carrying costs and improved manufacturing overhead absorption.
- Government grant revenue fell sharply to $0.1 million from $2.4 million. The company exhausted remaining availability under its Department of Defense grant and did not expect meaningful grant revenue in the foreseeable future.
- Operating expenses rose $3.0 million, driven by higher research and development and selling, general and administrative spending.
- Inventory increased to $10.2 million from $6.4 million, reflecting demand planning and supply-chain requirements.
- Cerus converted all outstanding Series B preferred stock into 332,700 common shares, eliminating the $9.5 million preferred liquidation preference.
- The company sold approximately 4.5 million common shares during 2012 for approximately $13.8 million of net proceeds, resulting in dilution.
Guidance, outlook, risks and unusual items
- Management expected product revenue to continue increasing as market adoption expands, but did not provide quantitative revenue or earnings guidance.
- Research and development spending was expected to increase for red blood cell studies, potential European Phase III trials, U.S. in vitro and clinical work, and modular FDA submissions for plasma and potentially platelets.
- In February 2013, the FDA indicated that existing clinical and European haemovigilance data could support a proposed modular PMA submission for platelets without additional Phase III trials at that time. The FDA could still require additional trials and post-marketing studies.
- The plasma modular PMA process was underway and was expected to take more than one year. U.S. approval for either platelet or plasma products had not been obtained.
- The red blood cell program required additional studies, regulatory approvals, commercial configuration work and substantial additional capital. Management did not expect approval for a number of years, if ever.
- Cerus recorded $0.9 million of warranty costs related to defective or potentially defective products, a $1.7 million inventory write-down, and a $1.8 million current asset for an accepted warranty claim against Fresenius for replacement products or credits.
- The company relies on Fresenius as the sole manufacturer of platelet and plasma disposable kits and relies on single-source suppliers for several other components. Supply interruptions, nonconformities, product recalls or obsolete components could materially affect sales and margins.
- Product revenue was concentrated: three customers accounted for 51% of product revenue in 2012. The company also faces concentrated blood-bank markets, reimbursement uncertainty, foreign-exchange exposure and competition from pathogen testing and alternative pathogen-inactivation technologies.
- The Comerica agreement required a minimum cash balance of $2.5 million and minimum revenue covenants. Cerus reported compliance at December 31, 2012; noncompliance could accelerate repayment.
- Ernst & Young issued unqualified opinions on the financial statements and internal control over financial reporting. Management reported effective disclosure controls and internal controls.
Most important facts for an investor to verify
- Whether product revenue growth and the 44% product gross margin were sustained after 2012, particularly after warranty-related inventory issues.
- Cash burn, remaining financing capacity, equity issuance and dilution, and the company’s ability to refinance or repay the Comerica facilities.
- Status, timing, cost and FDA response to the modular PMA submissions for the platelet and plasma systems.
- Progress, funding requirements and safety results for the red blood cell clinical program.
- Resolution and economic recovery of the Fresenius warranty claim, including replacement products or credit notes.
- Customer and distributor concentration, reimbursement developments and adoption trends in Europe and other commercial markets.
- Continuity and terms of single-source manufacturing and supply agreements, including the Fresenius agreement scheduled to extend through December 31, 2013 and other supplier commitments.